Characterization of Weight Loss with Nerandomilast in Patients with Autoimmune Interstitial Lung Disease and Progressive Pulmonary Fibrosis in the FIBRONEER-ILD Trial (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1775; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available
Clinical • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases
|
|
Anna-Maria Hoffmann-Vold, MD, PhD
|